title: LDA-SVM-based EGFR mutation model for NSCLC brain metastases: an observational study.
abstract: Epidermal growth factor receptor (EGFR) activating mutations are a predictor of tyrosine kinase inhibitor effectiveness in the treatment of non-small-cell lung cancer (NSCLC). The objective of this study is to build a model for predicting the EGFR mutation status of brain metastasis in patients with NSCLC. Observation and model set-up. This study was conducted between January 2003 and December 2011 in 6 medical centers in Southwest China. The study included 31 NSCLC patients with brain metastases. Eligibility requirements were histological proof of NSCLC, as well as sufficient quantity of paraffin-embedded lung and brain metastases specimens for EGFR mutation detection. The linear discriminant analysis (LDA) method was used for analyzing the dimensional reduction of clinical features, and a support vector machine (SVM) algorithm was employed to generate an EGFR mutation model for NSCLC brain metastases. Training-testing-validation (3 : 1 : 1) processes were applied to find the best fit in 12 patients (validation test set) with NSCLC and brain metastases treated with a tyrosine kinase inhibitor and whole-brain radiotherapy. Primary and secondary outcome measures: EGFR mutation analysis in patients with NSCLC and brain metastases and the development of a LDA-SVM-based EGFR mutation model for NSCLC brain metastases patients. EGFR mutation discordance between the primary lung tumor and brain metastases was found in 5 patients. Using LDA, 13 clinical features were transformed into 9 characteristics, and 3 were selected as primary vectors. The EGFR mutation model constructed with SVM algorithms had an accuracy, sensitivity, and specificity for determining the mutation status of brain metastases of 0.879, 0.886, and 0.875, respectively. Furthermore, the replicability of our model was confirmed by testing 100 random combinations of input values. The LDA-SVM-based model developed in this study could predict the EGFR status of brain metastases in this small cohort of patients with NSCLC. Further studies with larger cohorts should be carried out to validate our findings in the clinical setting.
authors: From the Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University (NH, GW, CC, DW, X-QY, YW, Z-ZY); College of Computer Science, Chongqing University, Chongqing, P.R. China (Y-HW, Z-SH); Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA (S-FC); Eighth Department (G-DL); Department of Respiration (YH); Department of Pathology, Daping Hospital, (H-LX); Department of Nuclear Medicine, Southwest Hospital, (D-DH); Department of Radiology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, P.R. China (K-LX); and Department of Minimally Invasive Interventional Radiology, Yunnan Tumor Hospital, Third Hospital Affiliated of Kunming Medical University, Kunming, P.R. China (MH).
authors: Nan
authors: N
authors: Hu
authors: Ge
authors: G
authors: Wang
authors: Yu-Hao
authors: YH
authors: Wu
authors: Shi-Feng
authors: SF
authors: Chen
authors: Guo-Dong
authors: GD
authors: Liu
authors: Chuan
authors: C
authors: Chen
authors: Dong
authors: D
authors: Wang
authors: Zhong-Shi
authors: ZS
authors: He
authors: Xue-Qin
authors: XQ
authors: Yang
authors: Yong
authors: Y
authors: He
authors: Hua-Liang
authors: HL
authors: Xiao
authors: Ding-De
authors: DD
authors: Huang
authors: Kun-Lin
authors: KL
authors: Xiong
authors: Yan
authors: Y
authors: Wu
authors: Ming
authors: M
authors: Huang
authors: Zhen-Zhou
authors: ZZ
authors: Yang
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002681:China; D016002:Discriminant Analysis; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D060388:Support Vector Machine
chemical_list: D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases
references: J Thorac Oncol. 2007 May;2(5):430-9
references: 17473659
references: J Clin Oncol. 2006 Nov 1;24(31):5079-90
references: 17075127
references: Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1-9
references: 6154024
references: Neuro Oncol. 2006 Apr;8(2):137-44
references: 16510849
references: Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):669-73
references: 2646260
references: Zhongguo Fei Ai Za Zhi. 2013 Jan;16(1):25-32
references: 23327870
references: Science. 2004 Jun 4;304(5676):1497-500
references: 15118125
references: Br J Cancer. 2008 Sep 16;99(6):923-9
references: 19238633
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: J Clin Oncol. 2013 Mar 1;31(7):895-902
references: 23341526
references: J Thorac Oncol. 2011 Jul;6(7):1287-9
references: 21847041
references: J Thorac Oncol. 2009 Jul;4(7):809-15
references: 19487967
references: Ann Oncol. 2013 Apr;24(4):993-9
references: 23129122
references: Artif Intell Med. 2010 Feb-Mar;48(2-3):129-37
references: 20005686
references: J Exp Clin Cancer Res. 2011 Mar 17;30:30
references: 21414214
references: Clin Cancer Res. 2008 Jan 1;14(1):162-8
references: 18172267
references: Eur Respir J. 2011 Mar;37(3):624-31
references: 20595147
references: J Thorac Oncol. 2014 Feb;9(2):195-9
references: 24419416
references: J Thorac Oncol. 2010 Jul;5(7):950-5
references: 20479691
references: J Mol Diagn. 2008 May;10(3):242-8
references: 18403609
references: Cancer Inform. 2007 Feb 14;2:87-97
references: 19458761
references: Cancer. 1995 Jan 1;75(1 Suppl):191-202
references: 8000996
references: Nonlinear Biomed Phys. 2011 Jul 19;5:5
references: 21771289
references: J Clin Oncol. 1988 Mar;6(3):543-51
references: 3280744
references: Asian Pac J Cancer Prev. 2012;13(3):909-14
references: 22631670
references: N Engl J Med. 2009 Sep 3;361(10):958-67
references: 19692684
references: J Clin Oncol. 2009 Mar 1;27(7):1091-9
references: 19188679
references: Med Phys. 2007 Oct;34(10):3808-14
references: 17985626
references: Med Phys. 2008 Nov;35(11):5098-109
references: 19070244
references: Breast Cancer Res Treat. 2011 Apr;126(2):407-20
references: 20490655
references: Hum Pathol. 2010 Jan;41(1):94-102
references: 19740513
references: Clin Lung Cancer. 2011 Nov;12(6):380-6
references: 21729655
references: Dis Markers. 2010;29(5):231-42
references: 21206008
references: Clin Cancer Res. 2009 Jul 15;15(14):4554-60
references: 19584155
references: Cancer Res. 2006 Oct 1;66(19):9601-8
references: 17018617
references: J Clin Oncol. 1988 Sep;6(9):1474-80
references: 3047337
references: Am J Clin Pathol. 2010 Jun;133(6):922-34
references: 20472851
references: Pathol Oncol Res. 2011 Jun;17(2):435-41
references: 21193980
references: Ann Oncol. 2009 Apr;20(4):696-702
references: 19088172
references: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references: 17237035
references: J Thorac Oncol. 2009 Oct;4(10):1212-20
references: 19687761